VISCHER advises EraCal on €235m licensing to Novo Nordisk
EraCal Therapeutics AG (“EraCal”), a Swiss biotech start-up company focusing on the fight of obesity, has licensed its main asset to Novo Nordisk for a total amount of EUR 235m in a collaboration and license deal. VISCHER advised EraCal on all legal issues related to the transaction.
The VISCHER team included Christian Wyss (pictured) (Partner, Corporate/M&A), Pauline Pfirter (Senior Associate, Corporate/M&A) and Lukas Wendt (Associate, Corporate/M&A).
